FDA's Proposed Rule For Oversight Of Laboratory Developed Te

After an over decade-long discourse amongst interested stakeholders, on October 3, 2023, FDA unveiled its proposed rule and policy to increase oversight over LDTs.

Related Keywords

, York State Department Of Health , Clinical Laboratory Evaluation Program , Veterans Health Administration , Public Health Surveillance , Academic Medical Centers Amcs , Clinical Laboratory Improvement Amendments , Tests Subject , Phaseout Policy , Leukocyte Antigen , Law Enforcement , Public Health , Remain Under Active , Federal Food , Cosmetic Act , Blood Donor Screening , Phaseout Timeline , Device User Fee Amendments , Unique Device Identification , Device Exemption , Small Business Determination , Small Business , Devices Program , Safer Technologies Program , Medical Centers , New York State Department , Veterans Health , Q Submission Program , Consolidated Appropriations Act , Sunshine Act , Mondaq , Fdas Proposed Rule For Oversight Of Laboratory Developed Tests Part Ii Fda Amp 39s Phaseout Policy X2013 Key Considerations Open Questions , Compliance , Food , Drugs , Healthcare , Life Sciences , Iotechnology Amp Nanotechnology ,